This helped pharmaceutical companies develop selective inhibitors of mutated BRAF – including vemurafenib and dabrafenib, which have been approved to treat melanoma. These treatments are frequently ...

which has previously won regulatory approvals for the combination as treatment for BRAF-mutated melanoma, non-small cell lung cancer (NSCLC) and thyroid cancers. Use of Tafinlar/Mekinist in ...

This page includes links to articles highlighting the top skin cancer research published on Cancer Therapy Advisor in 2024.

Researchers concluded that dabrafenib and trametinib appeared active in the second-line adjuvant setting, “although more follow up is required to confirm.” ...

NeoGenomics' newly published study shows how ctDNA in MRD may enable earlier identification of disease recurrence for ...

Similarly for BRAF mutant melanoma, it showed a confirmed objective response rate with odds ratio 1.54 and same applied to mucosal melanoma with odds ratio of 1.59 and patients who have high LDH more ...

And if advanced melanoma is found, you may need additional imaging and blood tests to help determine the best treatment plan. A pathologist may also examine your tissue sample under a microscope to ...

Peter Mac scientists have found a way to use the powerful gene editing tool CRISPR to silence cancer-causing gene mutations ...

The duo is already approved to treat BRAF-mutated melanoma, and almost doubled survival ... with less advanced disease or as a first-line treatment.” A study called ANCHOR-CRC is already ongoing ...

“We certainly know of cases where patients have received inappropriately extensive treatment for a lesion that didn’t need it, and the reverse is definitely true,” he said. Melanoma patient ...